Trial · NCT00175019
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. | Month 1 | Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 1 visit was summarized. |
| Primary | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12. | Month 12 | Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized. |
| Primary | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24. | Month 24 | Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized. |
| Primary | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36. | Month 36 | Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized. |
| Primary | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment. | Last Visit on treatment (up to 40 months). | The percentage of subjects whose serum urate was \<6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment. |
| Secondary | Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment. | Last Visit on treatment (up to 40 months). | The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment. |
| Secondary | Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline. | Month 12 | The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized. |
| Secondary | Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline. | Month 24 | The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized. |
| Secondary | Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline. | Month 36 | The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized. |
| Secondary | Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline. | Final Visit (up to 40 months). | The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized. |
| Secondary | Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit. | Final Visit (up to 40 months). | The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized. |
| Secondary | Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12. | Month 12 | The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized. |
| Secondary | Percentage of Subjects Requiring Treatment for Gout Flare After Month 12. | After Month 12 to Final Visit | The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00175019/registered